The neurotransmitter gamma-aminobutyric acid (GABA) activates more tha
n one receptor subtype, including the metabotropic receptor, GABA(B).
GABA(B) receptors are located at pre- and postsynaptic sites on centra
l neurons and mediate changes in the membrane conductance of potassium
and calcium ions. This influences transmitter release as well as affe
cting neuronal activity directly. The GABA(B) system can be modified b
y receptor ligands. This is currently exploited clinically, within the
spinal cord, with the use of the GABA(B) agonist baclofen to treat sp
asticity and, to a lesser degree, trigeminal neuralgia. However, other
potential uses of GABA(B) ligands may be on the horizon in relation t
o absence epilepsy, cognitive impairment and depression.